FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162313339> ?p ?o ?g. }

• W2162313339 endingPage "445" @default.
• W2162313339 startingPage "437" @default.
• W2162313339 abstract "Dopamine agonists are indicated as primary therapy for PRL-secreting pituitary adenomas, while controversial results have been reported in nonfunctioning adenomas (NFA).To evaluate whether the in vivo visualization of dopamine D2 receptor expression detected by pituitary scintigraphy using 123I-methoxybenzamide (123I-IBZM) was correlated with the response to chronic treatment with quinagolide or cabergoline.10 patients affected with NFA (5 men and 5 women, age ranging between 25 and 50 years), and 10 with PRL-secreting naive macroadenomas (3 men and 7 women, age ranging between 22 and 59 years), serving as control.All patients underwent an acute test with quinagolide: at 3-day intervals and in random order all patients received the drug (0.075 mg at 0800 h), or placebo. Blood samples were taken 15 and 5 minutes before and every 30 minutes for 6 h after drug or placebo administration. The test was considered positive when PRL and/or alpha-subunit levels decreased >/=50% as compared to baseline levels. After 6 months of treatment, 10 patients were randomised to continue the treatment with quinagolide and the remaining 10 received cabergoline for the remaining 6 months. The doses of quinagolide and cabergoline ranged from 0.075 to 0.6 mg/day and from 0.5 to 3 mg/week, respectively. At study entry, a magnetic resonance imaging (MR) study of the pituitary region and 123I-IBZM pituitary scintigraphy were performed. MR was repeated after 12 months of treatment to evaluate tumour shrinkage: reduction of tumour volume = 80% in prolactinomas and = 50% in NFA was considered significant. Basal PRL levels were 9495.0 +/- 1131.6 mU/l in prolactinomas and 602.4 +/- 50.5 mU/l in NFA.The scintigraphy was negative in 6 out of 10 patients with NFA. Moderate uptake was observed in 3 patients with prolactinoma and 2 patients with NFA whereas intense uptake was observed in the remaining 7 patients with prolactinoma and 2 patients with NFA. Among the 8 patients with NFA and high circulating alpha-subunit levels, the acute test was negative in 5 while it was positive in the remaining 3 patients. The acute test was positive in all 10 patients with prolactinoma. After 12 months of treatment with quinagolide and cabergoline, circulating PRL levels were decreased in all 10 patients with prolactinoma (571.8 +/- 255.9 mU/l), being normalized in 7 patients. Suppression of PRL levels was found in all 10 patients with NFA (89.5 +/- 2.3 mU/l). A significant reduction of alpha-subunit levels was obtained in 9 out of 10 patients with NFA: in 4 out of 8 patients alpha-subunit levels were normalized. Significant adenoma shrinkage was recorded in 4 patients with prolactinoma among the 7 with intense pituitary uptake of 123I-IBZM. Significant adenoma shrinkage was recorded only in the 2 out of 10 patients with NFA with intense pituitary uptake of 123I-IBZM. A significant positive correlation was found between the degree of uptake (considered as score) and the response to quinagolide or cabergoline treatment (considered as percent hormone suppression) either in patients affected with PRL-secreting adenoma (r = 0.856, P < 0.005) or in those affected with NFA (r = 0.787, P < 0.05).An intense 123I-IBZM uptake in patients with non-functioning adenomas was predictive of a good response to a chronic treatment with quinagolide and cabergoline. This result suggests that a pituitary 123I-IBZM scintigraphy could be considered in selected patients with non-functioning adenomas before starting medical treatment with dopamine agonists." @default.
• W2162313339 created "2016-06-24" @default.
• W2162313339 creator A5010778880 @default.
• W2162313339 creator A5039375389 @default.
• W2162313339 creator A5043206112 @default.
• W2162313339 creator A5048037056 @default.
• W2162313339 creator A5070034601 @default.
• W2162313339 creator A5077499862 @default.
• W2162313339 creator A5087293057 @default.
• W2162313339 creator A5089152448 @default.
• W2162313339 date "2000-04-01" @default.
• W2162313339 modified "2023-09-23" @default.
• W2162313339 title "Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with ¹²³ I-methoxybenzamide" @default.
• W2162313339 cites W153910647 @default.
• W2162313339 cites W1967676176 @default.
• W2162313339 cites W1974019100 @default.
• W2162313339 cites W1977533442 @default.
• W2162313339 cites W1977800889 @default.
• W2162313339 cites W1982514864 @default.
• W2162313339 cites W1983498173 @default.
• W2162313339 cites W1993563004 @default.
• W2162313339 cites W1999549590 @default.
• W2162313339 cites W2006757721 @default.
• W2162313339 cites W2008108754 @default.
• W2162313339 cites W2010772266 @default.
• W2162313339 cites W2016054538 @default.
• W2162313339 cites W2023895494 @default.
• W2162313339 cites W2024881534 @default.
• W2162313339 cites W2037846018 @default.
• W2162313339 cites W2045287329 @default.
• W2162313339 cites W2047638867 @default.
• W2162313339 cites W2049486103 @default.
• W2162313339 cites W2071445796 @default.
• W2162313339 cites W2079391734 @default.
• W2162313339 cites W2079554572 @default.
• W2162313339 cites W2081855023 @default.
• W2162313339 cites W2094760586 @default.
• W2162313339 cites W2126269644 @default.
• W2162313339 cites W2140572454 @default.
• W2162313339 cites W2152997319 @default.
• W2162313339 cites W2154895266 @default.
• W2162313339 cites W2170712695 @default.
• W2162313339 cites W2222235304 @default.
• W2162313339 cites W4249269285 @default.
• W2162313339 doi "https://doi.org/10.1046/j.1365-2265.2000.00951.x" @default.
• W2162313339 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10762286" @default.
• W2162313339 hasPublicationYear "2000" @default.
• W2162313339 type Work @default.
• W2162313339 sameAs 2162313339 @default.
• W2162313339 citedByCount "53" @default.
• W2162313339 countsByYear W21623133392012 @default.
• W2162313339 countsByYear W21623133392013 @default.
• W2162313339 countsByYear W21623133392014 @default.
• W2162313339 countsByYear W21623133392015 @default.
• W2162313339 countsByYear W21623133392016 @default.
• W2162313339 countsByYear W21623133392017 @default.
• W2162313339 countsByYear W21623133392018 @default.
• W2162313339 countsByYear W21623133392019 @default.
• W2162313339 countsByYear W21623133392020 @default.
• W2162313339 countsByYear W21623133392021 @default.
• W2162313339 countsByYear W21623133392022 @default.
• W2162313339 countsByYear W21623133392023 @default.
• W2162313339 crossrefType "journal-article" @default.
• W2162313339 hasAuthorship W2162313339A5010778880 @default.
• W2162313339 hasAuthorship W2162313339A5039375389 @default.
• W2162313339 hasAuthorship W2162313339A5043206112 @default.
• W2162313339 hasAuthorship W2162313339A5048037056 @default.
• W2162313339 hasAuthorship W2162313339A5070034601 @default.
• W2162313339 hasAuthorship W2162313339A5077499862 @default.
• W2162313339 hasAuthorship W2162313339A5087293057 @default.
• W2162313339 hasAuthorship W2162313339A5089152448 @default.
• W2162313339 hasConcept C126322002 @default.
• W2162313339 hasConcept C126894567 @default.
• W2162313339 hasConcept C134018914 @default.
• W2162313339 hasConcept C142724271 @default.
• W2162313339 hasConcept C204787440 @default.
• W2162313339 hasConcept C27081682 @default.
• W2162313339 hasConcept C2777428134 @default.
• W2162313339 hasConcept C2779064019 @default.
• W2162313339 hasConcept C2779318953 @default.
• W2162313339 hasConcept C2779832395 @default.
• W2162313339 hasConcept C2779902710 @default.
• W2162313339 hasConcept C513476851 @default.
• W2162313339 hasConcept C71315377 @default.
• W2162313339 hasConcept C71924100 @default.
• W2162313339 hasConceptScore W2162313339C126322002 @default.
• W2162313339 hasConceptScore W2162313339C126894567 @default.
• W2162313339 hasConceptScore W2162313339C134018914 @default.
• W2162313339 hasConceptScore W2162313339C142724271 @default.
• W2162313339 hasConceptScore W2162313339C204787440 @default.
• W2162313339 hasConceptScore W2162313339C27081682 @default.
• W2162313339 hasConceptScore W2162313339C2777428134 @default.
• W2162313339 hasConceptScore W2162313339C2779064019 @default.
• W2162313339 hasConceptScore W2162313339C2779318953 @default.
• W2162313339 hasConceptScore W2162313339C2779832395 @default.
• W2162313339 hasConceptScore W2162313339C2779902710 @default.
• W2162313339 hasConceptScore W2162313339C513476851 @default.
• W2162313339 hasConceptScore W2162313339C71315377 @default.

• next